Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quetiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.85 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.85 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.85 |
| ▸ | DRD3 | P35462 | 3/20 | 0.85 |
| ▸ | DRD4 | P21917 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 2/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.85 |
| ▸ | DRD1 | P21728 | 2/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.85 |
| ▸ | HRH1 | P35367 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quetiapine SCHEMBL29487500 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL122596 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL31678628 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL4962023 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL41336 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL390694 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL30990390 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5325208 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL678457 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5070765 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10452 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-224221240-U | Quetiapine fumarate tablet medicament column type hopper mixer | 华裕(无锡)制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260034151-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2026-02-05 | — | — | US | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250319073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | claimed |
| US-20250288539-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-20250275924-A1 | Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions | ATTILLAPS HOLDINGS INC. | 2025-09-04 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| EP-1026950-A1 | TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS | CORTEX PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| JP-2000507544-A | — | — | 2000-06-20 | — | — | JP | claimed |
| WO-2000021522-A1 | USE OF METFORMIN TO COUNTERACT WEIGHT GAIN ASSOCIATED WITH VALPROATE AND OTHER PSYCHOTROPIC MEDICATIONS | CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999021422-A1 | TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS | CORTEX PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| EP-0906104-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1997035584-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997032037-A1 | ASSESSMENT OF THE RESPONSIVENESS OF INDIVIDUALS TO MODULATORS OF THE 5-HT2 RECEPTORS, ESPECIALLY THE 5-HT2A RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 1997-09-04 | — | — | WO | claimed |
| WO-1997021833-A1 | METHOD OF PREDICTING A SUBJECTS RESPONSE TO NEUROLEPTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-19 | — | — | WO | claimed |
| WO-1996031621-A2 | METHOD FOR DETERMINING THE RESPONSIVENESS OF INDIVIDUALS TO 5-HT2 RECEPTOR MODULATING AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-10 | — | — | WO | claimed |